Voya Investment Management LLC Has $6.70 Million Stake in Medpace Holdings, Inc. $MEDP

Key Points

• Voya Investment Management LLC increased its stake in Medpace Holdings, Inc. by 7.6%, accumulating a total of 21,976 shares valued at approximately $6.7 million as of its latest SEC filing.
• Insider trading was notable, with CFO Kevin M. Brady selling 12,000 shares for approximately $5.45 million, decreasing his position by 66.67%, while insiders overall sold 161,266 shares valued at over $74 million in the last three months.
• Medpace reported a strong performance for the last quarter, with earnings per share of $3.10, surpassing estimates, and a revenue increase of 14.2% year-over-year, leading to updated FY 2025 guidance of 13.760-14.53 EPS.

Voya Investment Management LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,976 shares of the company's stock after acquiring an additional 1,560 shares during the quarter. Voya Investment Management LLC owned approximately 0.08% of Medpace worth $6,696,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Militia Capital Partners LP increased its holdings in shares of Medpace by 3,839.4% in the 1st quarter. Militia Capital Partners LP now owns 13,000 shares of the company's stock valued at $3,961,000 after acquiring an additional 12,670 shares during the last quarter. Inspire Investing LLC bought a new stake in shares of Medpace in the 1st quarter valued at approximately $2,059,000. Strs Ohio bought a new position in Medpace during the 1st quarter worth $10,055,000. Geneos Wealth Management Inc. grew its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares during the last quarter. Finally, Intech Investment Management LLC grew its stake in Medpace by 61.1% during the 1st quarter. Intech Investment Management LLC now owns 21,354 shares of the company's stock worth $6,506,000 after buying an additional 8,097 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

NASDAQ:MEDP traded down $3.34 during trading hours on Friday, hitting $498.60. 744,026 shares of the company's stock traded hands, compared to its average volume of 316,492. The firm has a market cap of $14.01 billion, a P/E ratio of 37.07, a P/E/G ratio of 3.14 and a beta of 1.44. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $506.55. The stock's fifty day moving average price is $446.89 and its two-hundred day moving average price is $355.45.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.Medpace's quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on MEDP. Truist Financial upped their price objective on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Rothschild Redb downgraded Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and upped their price objective for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Deutsche Bank Aktiengesellschaft boosted their price target on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Finally, William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Reduce" and an average price target of $422.27.

Insider Buying and Selling at Medpace

In other news, CEO August J. Troendle sold 36,196 shares of Medpace stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $475.90, for a total transaction of $17,225,676.40. Following the completion of the sale, the chief executive officer directly owned 925,799 shares in the company, valued at $440,587,744.10. The trade was a 3.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin M. Brady sold 12,000 shares of Medpace stock in a transaction dated Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares of the company's stock, valued at approximately $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 over the last quarter. Insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.